Oral SERD Promising in ER-Positive Breast Cancer With ESR1 Mutations

The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective response rate among 40 heavily pretreated women with estrogen receptor (ER)-positive, HER2-negative breast cancer.

Source: CancerNetwork - June 6, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Conferences/ASCO Breast Cancer News Source Type: news